Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Innovation Council · Ended early

Nexdiag Revolutionising allergies diagnostics with the next generation of ultra-sensitive highly multiplexed diagnostic tests based on micro-pearls

Coordinator
Nexdot, France
Runs
1 May 2023 to 31 July 2026
Status
Ended early
EU funding
€2.5m
Total cost
€3.6m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190186747

What the project is doing

In the project's own words, from its summary on CORDIS.

The WHO predicts that half of the European population will suffer from allergies. Allergies are a growing burden for our society, our healthcare system and companies that have to take staff off work due to disabling symptoms. Thanks to fluorescent µpearls and the discovery of Quantum Plates, Nexdot is developing a highly multiplexed diagnostic test that will allow to assay IgE on 500 allergens (and up to 1000) at once using only one drop of blood.

This innovation will revolutionize the way allergies are treated by reducing drastically the time to diagnostic and its associated cost (x10-20 reduction). Our technology could also be extended to serology tests, for detection of patient’s antibodies against infectious agents or cancer markers. It can be extended for global health for the easy and cost-effective detection of antigens as infectious or toxic agents in human, animals or environment for global health, or food for industry.

Topics

Who is involved

OrganisationCityCountryRole
NexdotRomainvilleFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI